Merck is gearing up for a patent cliff and just acquired Verona Pharma for $10 billion to expand its respiratory disease treatment lineup. With newer products like Ohtuvayre and Winrevair, Merck is diversifying beyond its reliance on Keytruda, which faces patent expiration soon. The stock has seen pressure due to this risk, but Merck’s solid dividend and valuation make it an attractive option. With a multipronged approach to new acquisitions and developments, Merck is positioning itself well for the post-Keytruda era, offering potential for growth and stability in the pharmaceutical market.

Read more at Nasdaq: Does This Move Make Merck Stock a Buy?